Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Case Based Panel Discussion - 2019 ALK Positive with Brain Mets, Radiation before ALK Inhibitor?
Author
Howard (Jack) West, MD
Image
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.

Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.

Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive asymptomatic brain metastases. Is the standard approach of focal radiation before beginning ALK inhibitor appropriate, or do you begin with the ALK Inhibitor?

To join the conversation, visit https://cancergrace.org/forum.  

For a full listing of these case based discussions, please visit https://cancergrace.org/sponsor/case-based-panel-discussions-2019-lung-cancer.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.